Legend Biotech
Legend Biotech Corporation, a prominent player in the biotechnology industry, is headquartered in the United States. Founded in 2014, the company has rapidly established itself as a leader in cell therapy, particularly in the development of innovative treatments for cancer. With a focus on CAR-T cell therapies, Legend Biotech's flagship product, cilta-cel, has garnered significant attention for its unique approach to targeting multiple myeloma. Operating primarily in the US and expanding its reach globally, Legend Biotech has achieved notable milestones, including strategic partnerships and advancements in clinical trials. The company is recognised for its commitment to advancing personalised medicine, positioning itself at the forefront of the biopharmaceutical landscape. With a robust pipeline and a dedication to transformative therapies, Legend Biotech continues to make significant strides in improving patient outcomes.
DitchCarbon Score
How does Legend Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Legend Biotech's score of 35 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Legend Biotech's reported carbon emissions
In 2023, Legend Biotech reported total carbon emissions of approximately 12,973,530 kg CO2e. This figure includes 770,000 kg CO2e from Scope 1 emissions, primarily from stationary combustion, and about 12,204,000 kg CO2e from Scope 2 emissions, which are associated with purchased electricity. Notably, the company has not disclosed any Scope 3 emissions data. Despite the significant total emissions, there are currently no specific reduction targets or initiatives outlined by Legend Biotech. The absence of documented climate pledges or reduction strategies suggests that the company may still be in the early stages of formalising its climate commitments. As the biopharmaceutical industry increasingly prioritises sustainability, it will be essential for Legend Biotech to establish clear goals and strategies to mitigate its carbon footprint in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 770,000 |
| Scope 2 | 12,204,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Legend Biotech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
